Document is current
Any future updates will be listed below
-
Authors
Abdel Jawad, Mohammad
Furtado, Remo H. M.
Esterline, Russell
Oscarsson, Jan
Gasparyan, Samvel B.
Koch, Gary G.
Martinez, Felipe
Mukhtar, Omar
Verma, Subodh
Langkilde, Anna Maria
Ambery, Philip
Patel, Shachi
Gosch, Kensey
Windsor, Sheryl L.
Soares, Ronaldo V. P.
Moia, Diogo D. F.
Aboudara, Matthew
Javaheri, Ali
Saraiva, J. F. Kerr
Maia, Lilia Nigro
Berwanger, Otavio
Sauer, Andrew J.
Kosiborod, Mikhail N.
-
Funding
Funding for this research was provided by:
AstraZeneca Pharmaceuticals LP (ESR-20-20653)
- License Information
-
More Information
Article History
Received: 28 April 2025
Accepted: 18 July 2025
First Online: 30 July 2025
Declarations
:
: This trial was approved by ethics committees at all study sites, and all participants provided written informed consent.
: All participantswere informed the results from this trial may be presented in articles when they provided written informed consent.
: Dr. Kosiborod: Grant/Research Support: Astra Zeneca, Boehringer Ingelheim and Pfizer. Honoraria: Astra Zeneca, Boehringer Ingelheim, Novo Nordisk. Consultant/Advisory Boards: 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, Astra Zeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Roche, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, Youngene Therapeutics. Stock options: Artera Health, Saghmos Therapeutics. Employment: AstraZeneca R&D, effective January 6, 2025. Dr. Sauer: Research Funding (Site Fees): AstraZeneca, CSL Vifor, NovoNordisk, Pfizer, RivusConsultant: 35Pharma, Abbott, Acorai, Amgen, Bayer, Boston Scientific, CSL Vifor, General Prognostics, Impulse Dynamics, Rivus, Story Health. Other Research Support (Data Analytic Center Fees): AstraZeneca, Vifor Pharma. Stock ownership: ISHI, Pulsli. Dr. Furtado reports research grants and personal fees from AstraZeneca, Bayer, Servier, and Apsen; and research grants (received from his institution) from Pfizer, Libbs, Brazilian Ministry of Health, and University Health Network. Drs. Oscarsson, Gasparyan, Esterline, Langkilde, and Ambery are shareholders and employed by AstraZeneca. Professor Gary G. Koch: Grant/Research Support: AbbVie, Acadia Pharmaceuticals, Aerovate Therapeutics, Amgen, AstraZeneca, Bayer, BioMarin, Cytokinetics, ENSHO, Galderma Research Development, Gilead, GlaxoSmithKline, HUYA Bioscience International, Intracellular Therapies, Ironwood, Johnson and Johnson, Kala, Merck, Momentum, Novartis, Otsuka, Pfizer, Regeneron Pharmaceuticals, REGENXBIO Inc, Renovion, Scholar Rock, Summit Therapeutics, UCB, vTv Therapeutics, Xylocor Therapeutics. The other authors report no disclosures.
